source
- Biohaven signs up to $795 million deal with SK Biopharma to license Kv7 platform and epilepsy assetBiohaven announced a licensing agreement with South Korean SK Biopharma centered on its Kv7 ion channel platform and lead epilepsy candidate opakalim. The deal could deliver up to $795 million, in…
- Akeso and Summit report ivonescimab meets primary endpoint in China Phase 3 biliary tract cancer trialAkeso Therapeutics and partner Summit Therapeutics announced that their bispecific antibody ivonescimab achieved the primary efficacy endpoint in a Phase 3 study conducted exclusively in China. Th…